MAIA Biotechnology Inc. (MAIA) Next Earnings Date & Expected ±10.6% Move

Per the Roarable RQD rating, MAIA scores 48 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 12/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 15/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillars are the cash engine and insider conviction, which together indicate that the reported business is not yet generating cash and that insider flow offers limited support. The strongest relative pillar is macro fit, which reflects a beta of 1.0 but does not offset the fundamental weakness. For a prospective investor, the rating frames the stock as one where the upside case rests almost entirely on future clinical and corporate developments rather than on current economics. Valuation cannot be anchored to earnings, since P/E and EPS are not available in source data, and the zero FCF yield means there is no present cash return to support the price. The 52-week range of $0.87 to $3.19 against a current price of $1.13 illustrates high price volatility relative to the company's disclosed fundamentals.

Per the SEC financials, reported revenue is $0.0M in both periods, with operating losses of $-24.3M in FY 2025 and $-17.0M in FY 2024. Net margin, gross margin, and operating margin are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3 out of 9, and Debt/Equity is 0.5. The reported cash balance is $0.0M in both periods, and debt is listed as N/A, so balance sheet posture cannot be fully characterized from the financial table alone.

Per the recent news wire, the principal catalyst is a headline reporting patient enrollment milestones in ongoing Phase 2 and pivotal Phase 3 non-small cell lung cancer trials, carried by multiple outlets within the last several hours. A separate report flagged MAIA among premarket movers on Nov. 2, 2026, marked as a catalyst item. Several items are general quote-page or seasonal-return listings with limited analytical content. A Benzinga headline references insider buying in biotech names, which is relevant to the insider pillar but is not quantified in the holders data. Risk watch items: the news wire contains no information on trial readouts, regulatory timelines, or financing. Per the Butterfly Supply-Chain Graph, no proprietary signals are present; supply chain: NONE.

• What are the current revenue, EPS, and cash balances, given that the filings list revenue and cash at $0.0M and EPS and debt as N/A?
• What is the timing and scope of the Phase 2 and Phase 3 trial readouts, and what regulatory milestones are scheduled?
• How is the company financing operating losses of roughly $-18.8M to $-22.4M per year, and what is the cash runway?
• Which specific insider and institutional transactions underlie the insider conviction and whale flow pillar scores?
• What is the basis for the 2.5 Altman Z-Score and 3/9 Piotroski F-Score, and how have these trended?